Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Shares Outstanding (Weighted Average) (2016 - 2026)

Ironwood Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 17 years, with the latest figure at $161.8 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 1.73% to $161.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $161.8 million, a 1.73% increase, with the full-year FY2025 number at $161.8 million, up 1.73% from a year prior.
  • Shares Outstanding (Weighted Average) hit $161.8 million in Q4 2025 for Ironwood Pharmaceuticals, roughly flat from $162.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for IRWD hit a ceiling of $162.2 million in Q4 2021 and a floor of $153.3 million in Q2 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $158.5 million across 5 years, with a median of $159.0 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): surged 101583.93% in 2021 and later decreased 5.34% in 2022.
  • Tracing IRWD's Shares Outstanding (Weighted Average) over 5 years: stood at $162.2 million in 2021, then decreased by 4.86% to $154.4 million in 2022, then increased by 0.69% to $155.4 million in 2023, then rose by 2.35% to $159.1 million in 2024, then grew by 1.73% to $161.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for IRWD at $161.8 million in Q4 2025, $162.2 million in Q3 2025, and $161.4 million in Q2 2025.